Who is sponsoring NCT06665217?

NCT06665217 is sponsored by Navy General Hospital, Beijing.

What condition does NCT06665217 study?

NCT06665217 studies Diffuse Large B-Cell Lymphoma.

Is NCT06665217 still recruiting?

NCT06665217 is currently not yet recruiting. Last updated 13 August 2025.

Last reviewed 2025-08-13 · How we verify

NCT06665217

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Glofitamab, Polatuzumab Vedotin, Zanubrutinib, Lenalidomide and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma

Not yet recruiting Phase 2 Last updated 13 August 2025

What this trial tests

Phase 2 trial testing Glofitamab, Polatuzumab Vedotin, Zanubrutinib, Lenalidomide and Prednisone as Induction Therapy in Diffuse Large B-Cell Lymphoma in 80 participants. Not yet recruiting.

Timeline

24 September 2025

Primary endpoint
1 January 2029

1 January 2030

Quick facts

Lead sponsor	Navy General Hospital, Beijing
Phase	Phase 2
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	80
Start date	24 September 2025
Primary completion	1 January 2029
Estimated completion	1 January 2030

Drugs / interventions tested

Glofitamab, Polatuzumab Vedotin, Zanubrutinib, Lenalidomide and Prednisone as Induction Therapy — full drug profile →

Conditions studied

Diffuse Large B-Cell Lymphoma — all drugs for Diffuse Large B-Cell Lymphoma →

Sponsor

Navy General Hospital, Beijing

Who can join

14 and older, any sex, with Diffuse Large B-Cell Lymphoma. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Overall Response Rate (ORR)
Time frame: 1 year
ORR was defined as the proportion of patients who achieved CR or PR as their best response

Sponsor's own description

The goal of this phase 2 trial is to test the safety and efficacy of G-Pola-ZLP as induction therapy in patients with DLBCL.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Molecular Mechanisms of Resistance to Bispecific Antibodies in Diffuse Large B-Cell Lymphoma.
Maher N, Al Deeban B, Diop NM, Assaf J, et al · · 2026 · PMID 42121895 · DOI 10.3390/cells15090794

Verify or expand the search:

Other recruiting trials for Diffuse Large B-Cell Lymphoma

Currently open trials in the same condition.

NCT06863402 — Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype · Phase 2 · recruiting
NCT07200375 — An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma · recruiting
NCT07070648 — Study on Predicting Response to Standard First-Line Treatment in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Using ct · recruiting
NCT07001540 — Evaluation of the Efficacy and Safety of Polatuzumab Vedotin Combined With Rituximab, Gemcitabine, and Oxaliplatin (Pola · Phase 2 · recruiting
NCT06803693 — Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL · Phase 2 · recruiting

Other Navy General Hospital, Beijing trials

Trials by the same sponsor.

NCT06382038 — Smart Technology Facilitated Patient-centered Care for Patients With Pulmonary Thromboembolism · NA · not yet recruiting
NCT07184788 — G-Pola-GemOx in Refractory/Relapsed Aggressive B-Cell Lymphoma · Phase 2 · not yet recruiting
NCT06938893 — Study on Cardiac Output Evaluation Based on Wearable Monitoring Data · not yet recruiting
NCT06744894 — SIL as Maintenance Therapy in Multiple Myeloma · Phase 2 · not yet recruiting
NCT06350344 — Smart Technology Facilitated Patient-centered Venous Thromboembolism Management · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06665217 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Navy General Hospital, Beijing
Last refreshed: 13 August 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06665217.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing